stage and grade, prognosis of disease and progression under therapy or survival of patients was demonstrated for various cancer types
. These studies constitute the promising potential of microRNAs as tumour classifiers and as prognostic and predictive biomarkers [5, 13, 14] . Recently, we summarized the current state of knowledge about microRNAs in urological tumours [15] . However, although renal cell carcinoma (RCC) is 1 of the 10 most frequent tumours [16] , the published data on microRNA in human RCC are surprisingly sparse [17, 18] . There were a few microarray-based studies including expression data from kidney only in comparison with other organs but not to RCC [10, [19] [20] [21] . During the revision of this paper, a report on microRNAs on RCC was published [22] . On the other hand, there are reports on the role of microRNAs in nontumoural kidney pathology. For example, 20 differently expressed microRNAs were recently identified in acute rejection after renal transplantation [23] . [24] .
This lack of data prompted us to (i ) determine and compare the expression profiles of microRNA in RCC in comparison with normal renal tissue, (ii ) explore possible associations between microRNA expression patterns and clinico-pathological data, (iii ) test the potential clinical usefulness of microRNAs as diagnostic and prognostic markers and (iv ) provide a reliable differential microRNA profile as a solid basis for further functional studies. This study focussed on clear cell RCC (ccRCC), the most common (75% of cases) renal cancer sub-type with the most serious prognosis

Materials and methods
Patients and tissue samples
The study was successively performed on two independent sample sets. Set one included 12 
RNA extraction
Matched malignant and non-malignant specimens from the same kidney were collected in RNAlater Stabilization Reagent (Qiagen, Hilden, Germany) . Total RNA including microRNAs was isolated using the miRNeasy Mini Kit (Qiagen) . RNA yield and quality were determined with a NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, Montchanin, DE) and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). 
Statistical analysis
Results
Characteristics of RNA samples
The mean A260/A280 ratio of all 84 RNA samples amounted to 1 
MicroRNA microarray expression data
Analyses were done initially with 12 matched malignant and nonmalignant sample pairs of set 1 ( Table 1 ). The stepwise statistical analyses of microarray intensity data are described and shown in the Supplemental Figure S1 as well as in Figs. 1 (Fig. 1) .
Furthermore, a hierarchical 2D-cluster analysis was applied without any statistical cuts on all 24 intensity profiles and 134
Fig. 1 Principal Component Analysis (PCA) for distinct separation of malignant and non-malignant sample groups. Intensity profiles of 12 different ccRCC tissue samples and matched non-malignant samples were reduced to lower dimension by PCA, a mathematical procedure that transforms a number of variables in expression data into a number of uncorrelated variables called principal components. PCA was used to identify uncorrelated variables and differences between sample groups and identified those components that explain the maximum amount of variance possible in the linearly transformed components between the sample groups. The dot plot illustrates the dimensionality reduction in intensity profiles by retaining those characteristics of the data set that contribute most to its variance, by keeping lower-order principal components and ignoring higher-order ones. Thereby two distinct and separated groups of samples were identified, namely, ccRCC tissue samples in green (on right) and non-malignant samples in pink (on left). All samples were grouped accordingly, except one non-malignant tissue sample (light pink dot on right) and one malignant tissue sample (light green dot on left).
reporters derived from the primary data-analysis steps. The Z-score was cropped to Ϫ2 to ϩ2 in the heat map (Fig. 2) (Fig. 3, left blank columns ϭ set 1) 
Two-dimensional cluster analysis across intensity profiles (on left) and microRNA reporters (on top). The Matrix Viewer displays hierarchical trees (on top and left) and a heat map (bottom). In the heat map, the log(ratio) data threshold was set at
Correlation between microRNAs and clinico-pathological data
The microRNA expression ratios were correlated among each other (Supplemental Table S1 [26] . To demonstrate an example, the corresponding targets of the strongest up-and down-regulated microRNAs were predicted using the computational programs TargetScan, PicTar and miRanda (Supplemental Table S3 ). Genes identified by at least two of the three programs were considered [27] . 
Putative miRNAs target genes
The putative targets of the dysregulated microRNAs provides a sound basis for further functional studies in ccRCC. For that purpose, various in silico methods for target gene prediction using different algorithms and ranking criteria have been developed
Discussion
The limited number of known microRNAs makes their analysis comparatively convenient, and a wealth of studies have attempted to use microRNAs for diagnostic purposes to classify tumours [28, 29] . Although few cases of human clear cell renal cell carcinoma (ccRCC) have already been included in comparative microRNA studies, a larger series of renal tumours has not been profiled yet [17, 30] . Nakada et al. [22] [31] . This is interesting, for conventional mRNA profiling techniques have yielded unsatisfactory results [32] .
In a brief global assessment of our findings, we found more microRNAs down-regulated (n ϭ 20) than up-regulated (n ϭ 13) considering a fold change of two, which is in line with previous studies [19, 22] . Also, the fold changes for the down-regulated microRNAs were slightly higher than for up-regulated microRNAs, which was particularly valid for miR-514 and miR-141. Interestingly, Gottardo et al. [17] analysed miR-profiles of 20 renal carcinomas and 3 non-matching normal renal tissues using an array platform that represented 245 microRNAs and found only (1.21-1.42 ), but no down-regulation of microRNAs. Also, there was no overlap with our data, which might be attributed to the different array platforms. A significantly better concordance was seen in comparison with the data of Nakada et al. [22] Table S3 ). The relationship between oncogenesis and ELAVL2 and PCDH2 was already proven in other tumours but not in ccRCC [33, 34] [8, 35] .
microRNAs significantly up-regulated in RCC (miR-28, miR-185, miR-7-2 and let-7f-2) with rather low mean fold changes
Among the list of differentially expressed microRNAs in ccRCC we also identified miR-21, a microRNA that has been implicated in blocking apoptosis in glioblastoma cells [36] . MiR-21 is also overexpressed in breast cancer and promotes cell proliferation [37] . Inhibition of apoptosis is a hallmark of cancer [38] , and likewise up-regulation of miR-21 appears to be a microRNA-hallmark of cancer because it has been found in breast, colon, endocrine neoplasms of the pancreas, lung, prostate and gastric cancer [5, 39] .
Another microRNA from our profile commonly found up-regulated in human tumours is miR-155. Coded by the gene BIC, which cooperates with c-myc to induce lymphomagenesis in a chicken model of lymphoma, miR-155 was the first microRNA that was ascribed oncogenic properties [40] . Recent studies found miR-155 highly up-regulated in lymphomas [41, 42] and various solid tumours [4, 7, 43, 44] . A prognostic value of miR-155 has been reported for non-small cell lung cancer [4] [54] . This novel approach appears promising and clearly warrants intense study. 
